Today: 9 June 2026
Browse Category

NYSE:MOH 23 October 2025 - 9 May 2026

UnitedHealth Stock Is Climbing Again: The Medical-Cost Bet Driving UNH Shares

UnitedHealth Stock Is Climbing Again: The Medical-Cost Bet Driving UNH Shares

UnitedHealth shares rose 2.8% to $379.98 on Friday, marking a third straight gain as investors responded to signs of easing medical-cost pressure. The company reported Q1 revenue of $111.7 billion and raised its full-year adjusted earnings outlook to over $18.25 a share. UnitedHealthcare also announced it will cut prior authorization requirements for 30% of services by the end of 2026. Humana and CVS shares also climbed sharply.
9 May 2026
···
Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum shares rose 10.6% to $617.81 in New York trading after S&P Dow Jones Indices said it will add the company to the S&P 500 on March 23. The move follows Nvidia’s $2 billion investment and a multiyear purchase agreement announced last week. Peers Coherent and Vertiv also gained. Lumentum reported second-quarter revenue up 65.5% to $665.5 million and forecast third-quarter revenue of up to $830 million.
9 March 2026
···········
UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth shares rose 0.3% to $277.44 in late morning trading Monday after CMS signaled a 0.09% Medicare Advantage payment increase for 2027. The stock remains under pressure after a 19% drop on Jan. 27, when the company warned of its first revenue decline since 1989. U.S. stocks were mixed, with the Dow down 0.3%. Comments on the CMS proposal are due by Feb. 25.
9 February 2026
··
Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Molina Healthcare plunged 25.5% after forecasting 2026 profit far below estimates and announcing a 2027 exit from Medicare Part D. Centene guided profit above expectations but dropped 3.7%, while Cigna rose 2.6% on a strong quarter but flagged a softer 2026 outlook. XLV gained 1.8%. Hims fell 10% after the FDA warned against mass-marketing compounded obesity drugs.
7 February 2026
···
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

The Dow Jones Industrial Average closed above 50,000 for the first time Friday, ending at 50,115.67, up 2.47%. Nvidia surged 7.8% as chip stocks rallied on AI spending hopes, while Amazon dropped 5.6% after projecting $200 billion in 2026 capital expenditures. Traders await delayed U.S. jobs and inflation reports next week.
6 February 2026
····
Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare shares plunged 27% to $129.77 after the company forecast 2026 adjusted EPS of at least $5.00, far below the $13.76 analyst consensus. Management cited higher medical costs and a sharp pullback in ACA Marketplace membership. The company posted a Q4 adjusted loss of $2.75 per share and plans to exit its Medicare Advantage Part D business in 2027.
6 February 2026
·
Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health shares fell 2.3% to $12.22 in premarket trading Friday after a 5.4% drop Thursday, as investors reacted to Molina Healthcare’s profit warning and exit from Medicare Part D. Molina’s stock plunged nearly 35% after hours, dragging other managed-care stocks lower. Oscar reports earnings Feb. 10, with investors watching for updates on 2026 enrollment and claims.
6 February 2026
····
Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare shares traded near $169.53 on Dec. 12, 2025, following an eighth straight session of gains. The stock’s rebound comes after a steep drop earlier in the year, with shares still well below the April high of $359.97. A new diabetes care partnership in South Carolina and renewed ACA policy uncertainty have influenced recent trading.
12 December 2025
·
MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

Molina Healthcare shares closed up 2.6% at $145.30 Monday on heavy volume after reports of a possible extension of ACA subsidies. The stock remains down over 50% from its 52-week high following an October earnings shock and ongoing class-action lawsuits. Market cap stood at $7.5 billion, with a P/E ratio near 9x. Intraday trading ranged from $141 to $151.
24 November 2025
·

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop